stockrow
Friday 6 November 2026
Export ORGO’s income statement to Excel — free account
Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024.
- Revenue
- −69.9%
- EPS
- −327.3%
- Free cash flow
- −2,048.8%
- Total debt
- +395.3%
Quarter to September 2026, against a year earlier
0.82
0.02
−2.38%
Follow ORGO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 4 | 2 |
| 5.63% | (7.68%) | (55.49%) | (81.71%) | ||
| 2.89% | (3.79%) | (24.40%) | (34.86%) | ||
ROIC |
12.78% | 0.97% | (19.97%) | (52.15%) | |
Return on Tangible Assets |
4.33% | (6.31%) | (43.23%) | (73.25%) | |
Average Days of Receivables |
140.68 | 82.90 | 80.54 | 96.10 | |
Free Cash Flow per Share |
(0.19) | 0.13 | 0.16 | 0.03 | |
Free Cash Flow |
(24.46) | 17.08 | 20.84 | 3.55 | |
Capital Expenditures |
(14.15) | (13.67) | (11.13) | (6.75) | |
| Other line items | |||||
Cash ROIC |
(6.01%) | 4.89% | 10.12% | 2.26% | |
Accounts Receivable Turnover |
3.45 | 4.67 | 4.13 | 2.69 | |
Accounts Payable Turnover |
4.52 | 5.24 | 4.60 | 3.87 | |
Inventory Turnover |
4.93 | 4.83 | 4.35 | 3.66 | |
Average Days of Payables |
84.80 | 74.83 | 78.84 | 67.66 | |
Days of Inventory on Hand |
78.63 | 74.34 | 78.81 | 80.32 | |
Tax Rate |
(0.21) | (0.36) | 1.42 | 0.58 | |
Research and Development Expense of Revenue |
7.90% | 9.53% | 12.45% | 14.69% | |
Selling, General and Administrative Expense of Revenue |
57.83% | 61.96% | 65.38% | 75.11% | |
Share Based Compensation of Revenue |
2.36% | 2.64% | 3.08% | 3.93% | |
Operating CF/Net income |
(0.65) | (1.64) | (0.30) | (0.07) | |
Depreciation/Fixed assets |
0.26 | 0.32 | 0.32 | 0.00 | |
Capex/Depreciation |
(0.53) | (0.41) | (0.34) | 0.00 | |
Revenue per Share |
4.45 | 4.03 | 3.56 | 2.73 | |
Operating CF per Share |
(0.08) | 0.24 | 0.25 | 0.08 | |
Capex per Share |
(0.11) | (0.11) | (0.09) | (0.05) | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026